Order Entry
United States
ContactUsLinkComponent
 
SDMA (Symmetric Dimethylarginine) ELISA, Eagle Biosciences, Inc.
  102994-984
 :  
SDMA (Symmetric Dimethylarginine) ELISA, Eagle Biosciences, Inc.
  102994-984
 :  EA214/96
 :  

Some Products May Appear Restricted

To ensure a smooth and speedy checkout, please log in to your account. Some items may show as restricted simply because you're not logged in.

If you do not have an account, you can register using our registration webform (https://www.avantorsciences.com/us/en/login/register)

 

If you're still seeing restrictions after logging in, certain products—like chemicals or medical devices—require additional account verification steps to be able to place an order. Some items may additionally require a specific license or customer documentation;  additional documentation will be requested for these items prior to shipment. 

 

  • Description:
    SDMA (Symmetric Dimethylarginine) ELISA
  • Size:
    1 kit
  • Cat. No.:
    102994-984
  • Supplier no.:
    SDM31-K01

 

 

SDMA (Symmetric Dimethylarginine) ELISA is intended to detect SDMA in serum or plasma.

  • Dynamic Range: 0.08 - 3.0 µmol/L
  • Sensitivity: 0.03 µmol/L
  • Incubation: 3 hours

Dosing of most drugs must be adapted in renal insufficiency, making accurate assessment of renal function an essential component of diagnostics in clinical medicine. Furthermore, even modest impairment of renal function has been recognized as a cardiovascular risk factor. As the most commonly used marker of renal excretory function, serum creatinine concentration, does not adequately respond to mild to moderate impairment of renal function, more sensitive markers for renal excretory function are urgently sought, especially in mild stages of renal impairment. SDMA is a methylated derivative of the amino acid L-arginine (symmetric dimethylarginine). SDMA is eliminated from the body exclusively by renal excretion; therefore SDMA plasma concentration is tightly related to renal function. Thus, quantification of plasma SDMA is an adequate means to assess renal function, as could be demonstrated in a series of recent clinical trials: In 18 clinical studies involving more than 2,100 samples systemic SDMA concentrations were highly correlated with inulin clearance as well as with various clearance estimates and better corresponded to mild renal function impairment than serum creatinine. Thus, SDMA exhibits properties of a reliable marker of renal function. Furthermore, there is evidence showing that elevated SDMA levels, as they may occur in renal function impairment, may prospectively indicate future risk of cardiovascular disease and mortality independently of the level of renal impairment.